Abstract Library
Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.
Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.
ENETS Abstract Search
#4141 BRAF/MEK combination treatment in a patient with BRAF mutated neuroendocrine carcinoma
Introduction: Preclinical studies indicate that BRAF V600E mutation is a druggable target in neuroendocrine carcinomas (NEC). Indeed, there are a few case reports that describe clinical response from BRAF inhibitor treatment of colorectal NEC.
Conference:
Presenting Author: Zhang L
Authors: Falkman L, Zhang L, Welin S, Crona J,
Keywords: Neuroendocrine carcinoma, BRAF V600E, Dabrafenib, Trametinib,
#3810 A patient with BRAF V600E mutated colon-NEC showing response to BRAF- and MEK inhibitors
Introduction: Preclinical studies have reported that the BRAF V600E mutation is a druggable target in colorectal neuroendocrine carcinomas (NECs). At least one case report has presented clinical success in the treatment of colorectal NEC using a BRAF inhibitor.
Conference:
Presenting Author:
Authors: Falkman L, Sundin A, Crona J, Wallin G, Welin S,
Keywords: neuroendocrine carcinoma, BRAF V600E, dabrafenib, trametinib, colorectal nec,
#3242 Establishment and characterization of a new neuroendocrine carcinoma cell model
Introduction: The development of treatment strategies for neuroendocrine carcinomas (NEC) requires in vitro models expressing NEC–specific targets. The CXC Chemokine Receptor Type 4 (CXCR4), that is expressed in NEC with decreasing differentiation, as well as factors involved in chemotherapy resistance may represent such targets.
Conference: 18th Annual ENETS Concerence (2021)
Presenting Author: Weich A
Authors: Weich A, Schreiner J, Rogoll D, Werner R, Meining A,
Keywords: neuroendocrine, net, CXCR4, Wnt signalling, beta-catenin, BON-1, QGP-1,
#3129 Colorectal NECs and MANECs: A monocenter pilot retrospective analysis
Introduction: Poorly-differentiated neuroendocrine carcinomas (NECs) and mixed adeno-neuroendocrine carcinomas (MANECs) are rare and aggressive neoplasms whose tumorigenesis pathways are still unknown and clinical management not universally shared.
Conference: 18th Annual ENETS Concerence (2021)
Presenting Author:
Authors: Laffi A, Spada F, Ranghiero A, Pisa E, Barberis M,
Keywords: mutational, genetic, neuroendocrine, NEC, MANEC, carcinogenesis, colorectal,
Introduction: The tumorigenesis of neuroendocrine neoplasm (NEN) are still ambiguous. The therapies of NENs in colon or rectum refer to adenocarcinomas (AC) when tumor metastasis, but the response was unsatisfactory which inspired us to explore the mutation difference.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Hu H
Authors: Cai W, Ge W, Wu D, Mao J, Hu H,
Keywords: Neuroendocrine neoplasm, Tumorigenesis, Mutation spectrums, Colorectal,